{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:59:48Z","timestamp":1790697588011,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cgh.2010.07.022","type":"journal-article","created":{"date-parts":[[2010,8,21]],"date-time":"2010-08-21T05:23:46Z","timestamp":1282368226000},"page":"1048-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti\u2013Tumor Necrosis Factor Therapy"],"prefix":"10.1016","volume":"8","author":[{"given":"Jean\u2013Fran\u00e7ois","family":"Rahier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Buche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin\u2013Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Duclos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavol","family":"Papay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cosnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2013Marie","family":"Reimund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"L\u00e9mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Delaporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2013Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2010.07.022_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the accent I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2010.07.022_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2010.07.022_bib3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2010.07.022_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the Accent II study","volume":"23","author":"Sands","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2010.07.022_bib5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2010.07.022_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2010.07.022_bib8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.cgh.2010.07.022_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British association of dermatologists' guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib12","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2010.07.022_bib13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"10.1016\/j.cgh.2010.07.022_bib15","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/S0151-9638(08)70547-7","article-title":"[Immune-mediated inflammatory diseases and psoriasis]","volume":"135","author":"Delaporte","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.cgh.2010.07.022_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2010.07.022_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000235582","article-title":"Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients","volume":"219","author":"Esmailzadeh","year":"2009","journal-title":"Dermatol Basel Switzerland"},{"key":"10.1016\/j.cgh.2010.07.022_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients","volume":"9","author":"Wollina","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/ni0901-777","article-title":"Sex differences in autoimmune disease","volume":"2","author":"Whitacre","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cgh.2010.07.022_bib20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.autrev.2006.10.001","article-title":"Gender and autoimmunity","volume":"6","author":"Zandman-Goddard","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.cgh.2010.07.022_bib21","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/art.21393","article-title":"Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis","volume":"52","author":"Ho","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2010.07.022_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/000155502320624069","article-title":"Palmoplantar pustulosis: an autoimmune disease precipitated by smoking?","volume":"82","author":"Hagforsen","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.cgh.2010.07.022_bib23","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2009.315","article-title":"Smoking and psoriasis: from epidemiology to pathomechanisms","volume":"129","author":"Naldi","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib24","first-page":"13","article-title":"Flexural versus plaque lesions in psoriasis: an immunohistochemical differentiation","volume":"15","author":"Vissers","year":"2005","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib25","first-page":"278","article-title":"Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease [in Spanish]","volume":"70","author":"Avila Alvarez","year":"2009","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.cgh.2010.07.022_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-2230.2005.01882.x","article-title":"Onset of flexural psoriasis during infliximab treatment for Crohn's disease","volume":"30","author":"Peramiquel","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2010.07.022_bib28","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2004.020719","article-title":"TNFalpha therapy in psoriatic arthritis and psoriasis","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2010.07.022_bib29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib31","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2010.07.022_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.cgh.2010.07.022_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cgh.2010.07.022_bib34","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1365-2133.2009.09329.x","article-title":"Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments","volume":"161","author":"Seneschal","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356510007871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356510007871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:06:52Z","timestamp":1761541612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356510007871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1542356510007871"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2010.07.022","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti\u2013Tumor Necrosis Factor Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2010.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}